Route21: a european gateway for preclinical development services

3 November 2023
  • Portfolio
  • /

    Route21 provides comprehensive preclinical development services through a network of partners for pharmaceutical companies and startups

    Rising demand for innovation in pharmaceuticals

    The pharmaceutical sector is rapidly evolving, with an increasing demand for innovation and efficient solutions. Preclinical development is a crucial phase where speed and accuracy are essential.

    This phase includes laboratory and animal studies to assess the safety and efficacy of a new drug before human trials. For instance, in the preclinical development of a hypertension drug, it’s verified that the molecule effectively lowers blood pressure without adverse effects.

    In this context, the industry seeks reliable partners and cutting-edge solutions to accelerate research and reduce time to market.

    Route21: a service network to accelerate drug development

    To reduce risks and accelerate the time-to-market of new drugs, Route21 was established in November 2022, born from Bio4Dreams‘ synergies in the innovation ecosystem of Eastern Europe.

    The entity leverages a network of international partners to provide pharmaceutical companies and startups with support and customized solutions at every stage of the preclinical development process.

    The range of services offered by Route21 covers the entire non-clinical drug development pipeline, from pharmacological target validation to therapeutic molecule optimization, including all synthesis and preclinical validation activities (see all services).

    A european gateway for preclinical development

    Route21 aims to position itself as a key reference and gateway for preclinical development in Europe. Its network of scientific collaborations and ongoing commitment to research and development make it a strategic ally, ready to meet emerging challenges and lead progress in the pharmaceutical sector.

    “Our goal is to change the paradigm of how preclinical research activities are performed, building a comprehensive ecosystem of research services that support every aspect of the drug’s non-clinical development phase.”

    Vladimir Kocsubej, CEO, Route21

    πŸ“— Learn more about Route21 and other entities in our portfolio.

    Route21: a european gateway for preclinical development services

    3 November 2023
  • Portfolio
  • /

    Route21 provides comprehensive preclinical development services through a network of partners for pharmaceutical companies and startups

    Rising demand for innovation in pharmaceuticals

    The pharmaceutical sector is rapidly evolving, with an increasing demand for innovation and efficient solutions. Preclinical development is a crucial phase where speed and accuracy are essential.

    This phase includes laboratory and animal studies to assess the safety and efficacy of a new drug before human trials. For instance, in the preclinical development of a hypertension drug, it’s verified that the molecule effectively lowers blood pressure without adverse effects.

    In this context, the industry seeks reliable partners and cutting-edge solutions to accelerate research and reduce time to market.

    Route21: a service network to accelerate drug development

    To reduce risks and accelerate the time-to-market of new drugs, Route21 was established in November 2022, born from Bio4Dreams‘ synergies in the innovation ecosystem of Eastern Europe.

    The entity leverages a network of international partners to provide pharmaceutical companies and startups with support and customized solutions at every stage of the preclinical development process.

    The range of services offered by Route21 covers the entire non-clinical drug development pipeline, from pharmacological target validation to therapeutic molecule optimization, including all synthesis and preclinical validation activities (see all services).

    A european gateway for preclinical development

    Route21 aims to position itself as a key reference and gateway for preclinical development in Europe. Its network of scientific collaborations and ongoing commitment to research and development make it a strategic ally, ready to meet emerging challenges and lead progress in the pharmaceutical sector.

    “Our goal is to change the paradigm of how preclinical research activities are performed, building a comprehensive ecosystem of research services that support every aspect of the drug’s non-clinical development phase.”

    Vladimir Kocsubej, CEO, Route21

    πŸ“— Learn more about Route21 and other entities in our portfolio.

    Route21: a european gateway for preclinical development services

    3 November 2023
  • Portfolio
  • /

    Route21 provides comprehensive preclinical development services through a network of partners for pharmaceutical companies and startups

    Rising demand for innovation in pharmaceuticals

    The pharmaceutical sector is rapidly evolving, with an increasing demand for innovation and efficient solutions. Preclinical development is a crucial phase where speed and accuracy are essential.

    This phase includes laboratory and animal studies to assess the safety and efficacy of a new drug before human trials. For instance, in the preclinical development of a hypertension drug, it’s verified that the molecule effectively lowers blood pressure without adverse effects.

    In this context, the industry seeks reliable partners and cutting-edge solutions to accelerate research and reduce time to market.

    Route21: a service network to accelerate drug development

    To reduce risks and accelerate the time-to-market of new drugs, Route21 was established in November 2022, born from Bio4Dreams‘ synergies in the innovation ecosystem of Eastern Europe.

    The entity leverages a network of international partners to provide pharmaceutical companies and startups with support and customized solutions at every stage of the preclinical development process.

    The range of services offered by Route21 covers the entire non-clinical drug development pipeline, from pharmacological target validation to therapeutic molecule optimization, including all synthesis and preclinical validation activities (see all services).

    A european gateway for preclinical development

    Route21 aims to position itself as a key reference and gateway for preclinical development in Europe. Its network of scientific collaborations and ongoing commitment to research and development make it a strategic ally, ready to meet emerging challenges and lead progress in the pharmaceutical sector.

    “Our goal is to change the paradigm of how preclinical research activities are performed, building a comprehensive ecosystem of research services that support every aspect of the drug’s non-clinical development phase.”

    Vladimir Kocsubej, CEO, Route21

    πŸ“— Learn more about Route21 and other entities in our portfolio.

    Route21: a european gateway for preclinical development services

    3 November 2023
  • Portfolio
  • /

    Route21 provides comprehensive preclinical development services through a network of partners for pharmaceutical companies and startups

    Rising demand for innovation in pharmaceuticals

    The pharmaceutical sector is rapidly evolving, with an increasing demand for innovation and efficient solutions. Preclinical development is a crucial phase where speed and accuracy are essential.

    This phase includes laboratory and animal studies to assess the safety and efficacy of a new drug before human trials. For instance, in the preclinical development of a hypertension drug, it’s verified that the molecule effectively lowers blood pressure without adverse effects.

    In this context, the industry seeks reliable partners and cutting-edge solutions to accelerate research and reduce time to market.

    Route21: a service network to accelerate drug development

    To reduce risks and accelerate the time-to-market of new drugs, Route21 was established in November 2022, born from Bio4Dreams‘ synergies in the innovation ecosystem of Eastern Europe.

    The entity leverages a network of international partners to provide pharmaceutical companies and startups with support and customized solutions at every stage of the preclinical development process.

    The range of services offered by Route21 covers the entire non-clinical drug development pipeline, from pharmacological target validation to therapeutic molecule optimization, including all synthesis and preclinical validation activities (see all services).

    A european gateway for preclinical development

    Route21 aims to position itself as a key reference and gateway for preclinical development in Europe. Its network of scientific collaborations and ongoing commitment to research and development make it a strategic ally, ready to meet emerging challenges and lead progress in the pharmaceutical sector.

    “Our goal is to change the paradigm of how preclinical research activities are performed, building a comprehensive ecosystem of research services that support every aspect of the drug’s non-clinical development phase.”

    Vladimir Kocsubej, CEO, Route21

    πŸ“— Learn more about Route21 and other entities in our portfolio.